Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
4basebio logo — Next generation gene therapy

4basebio

Next generation gene therapy

Founded 1997 United Kingdom Cambridge, United Kingdom 102 employees Grant Total: $299.20K Biotechnology, Health Care

General Information

Company Name 4basebio
Founded Year 1997
Location United Kingdom Cambridge, United Kingdom
Employees 102
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with 4basebio. To contact 4basebio, visit 4basebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does 4basebio compare?

A PDF of 4basebio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting 4basebio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About 4basebio

4basebio is a United Kingdom-based biotechnology startup focusing on next-generation gene therapy and vaccine development. With a founding year of 1997, the company has been pioneering the advancement of cell and gene therapies through its innovative technologies. Their synthetic DNA and mRNA solutions, alongside non-viral vectors for nucleic acid payload delivery, empower the development of customized and application-specific therapies and vaccines. The company's proprietary synthetic DNA technology offers a high level of customizability, rapid production, and enhanced safety profiles, effectively addressing the limitations of traditional DNA technologies. They currently offer four DNA construct types, catering to various applications such as viral and non-viral vector applications, genome editing, vaccines, therapeutics, and DNA vaccine applications. In addition to their DNA technology, 4basebio has developed Hermes™, a proprietary non-viral delivery system in the form of a nanoparticle vector. Hermes™ can be customized to target specific cells or tissues, combining the safety of lipid-based nanoparticles with the precision of a targeting system, thereby addressing the shortcomings associated with conventional viral vectors and non-targeted LNPs. The latest funding round of €299.20K came in the form of a grant investment from the la Caixa Foundation on 20 May 2020. This investment serves as a testament to the potential and direction of 4basebio, positioning them to further drive innovation and impact within the biotechnology and healthcare industries.

Business keywords: gene therapy, synthetic DNA, mRNA technology, non-viral vectors, nucleic acid delivery systems, genome editing, vaccines, therapeutics, nanoparticle technology, DNA manufacturing, life science technology

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €299.20K 1
la Caixa Foundation
la Caixa Foundation
20 May 2020

4basebio Alternatives & Competitors

View All Alternatives
4basebio vs
Gennao Bio
Gennao Bio United States

A genetic medicines company developing first-in-class, targeted nucleic acid therapeutics

Series A
5 employees
Biotechnology, Health Care
Compare 4basebio vs Gennao Bio
4basebio vs
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. United States

Enabling a new generation of genomic medicines for patients with high unmet medical needs.

Seed
13 employees
Biotechnology, Health Care
4basebio vs
Eterna Therapeutics
Eterna Therapeutics United States

Laser Focus with Relentless Execution

Post-IPO Debt
5 employees
Biotechnology, Health Care
View all alternatives

FAQ About 4basebio

Next generation gene therapy
4basebio was founded in 1997.
4basebio is headquartered in Cambridge, United Kingdom.
4basebio operates in Biotechnology and Health Care. Its work centres on gene therapy, synthetic DNA, mRNA technology and non-viral vectors.
4basebio has approximately 102 employees.
4basebio has completed 1 funding round, raising a total of $299.20K. The latest funding stage is Grant.
Top alternatives and competitors to 4basebio include Gennao Bio, Hopewell Therapeutics, Inc., Eterna Therapeutics, Integrated DNA Technologies, Senda Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
4basebio and Gennao Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for 4basebio, https://bouncewatch.com/company/4basebio, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout